PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform ...

BOSTON - Seaport Therapeutics, a clinical-stage biopharmaceutical company, has published new research demonstrating significant advancements in drug delivery through the lymphatic system using its ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...

After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved ... The drug – generated using Seaport's Glyph technology – recently started a phase ...

The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics. Karuna co-founder Daphne ...

US clinical-stage biotherapeutics company, Seaport Therapeutics’ investigational allopregnanolone prodrug, SPT-300, has been well tolerated in a Phase I trial. The company has published data ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team ...

“Seaport is advancing novel therapeutics that have proven clinical efficacy but had previously been held back by an issue we can now address with our Glyph platform. This financing enables the ...